Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | APG-2575 + unspecified immune checkpoint inhibitor |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
APG-2575 | APG 2575|APG2575|Lisaftoclax | BCL2 inhibitor 26 | APG-2575 is a small molecule that inhibits BCL-2, potentially resulting in increased apoptosis and enhanced antitumor activity in combination with other agents (Cancer Res July 1 2019 (79) (13 Supplement) 2058, PMID: 32093809). | |
unspecified immune checkpoint inhibitor | CTLA4 Antibody 25 Immune Checkpoint Inhibitor 155 PD-L1/PD-1 antibody 106 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|